July 2006

Gefitinib: A Cause of Pyogenic Granulomalike Lesions of the Nail

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Dermatol. 2006;142(7):927-947. doi:10.1001/archderm.142.7.939-a

Geftinib (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, Del) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non–small cell lung cancer (NSCLC). Recently, this agent has been a point of controversy. In patients who demonstrate a response, the results are often dramatic; however, such a response has occurred in as few as 10% of treated patients.1